News on protein analysis, clinical proteomics, biomarkers in genetics, genomics, and molecular diagnostics.
The test measures the multiple myeloma marker M protein and could prove more sensitive and less susceptible to interferences than existing assays.
They acknowledge that while the technical hurdles of proteomic test development have become manageable, commercialization is still a major challenge.
The proteomics firm is swapping 4 million of its shares for a 10 percent interest in CPR with the goal of moving into clinical trials and related research.
DiscernDx, which is backed by Khosla Ventures, stepped in to purchase API's assets after lender Square 1 Bank asserted a lien on the company late last year.
Based on technology developed at Mass General, the platform will allow the company and its customers to add protein detection to nucleic acid analysis.